摘要
目的 进一步观察阿司咪唑治疗慢性荨麻疹的疗效和安全性 ,并与氯雷他定进行比较。方法 采用多中心、随机双盲、平行对照试验。结果 11个试验中心共完成合格病例 42 9例 ,其中阿司咪唑组 2 15例 ,氯雷他定组 2 14例。治疗后 ,患者主、客观症状观察项目平均积分于服药第 7、14、2 1、2 8天均有下降 ,但两组间比较 (除皮肤划痕外 )均无统计学意义 (P >0 .0 5 ) ;停药 14天后各项指标 (除白天瘙痒外 ) ,两组比较阿司咪唑组明显优于氯雷他定组 ,且具有统计学意义 (P =0 .0 0 0 6～ 0 .0 476)。治疗结束时 ,阿司咪唑组痊愈 10 6(4 9.3 0 % )例 ,总有效率为 (73 .95 % ) 15 9/ 2 15 ;氯雷他定组痊愈 10 5 (4 9.0 7% )例 ,总有效率为 (70 .0 9% ) 15 0 / 2 14。两组间比较差异无统计学意义 (P >0 .0 5 )。结论 口服阿司咪唑或氯雷他定治疗慢性荨麻疹均具有良好疗效和安全性 ,但阿司咪唑停药
Objective This study was designed to compare the efficacy and safety of astemizole and loratadine for treatment of chronic idiopathic urticaria. Methods A multicentre, double-blind, randomized, comparative study was conducted.Results 429 subjects completed the trial in 11 centres, including 215 cases in astemizole group and 214 cases in loratadine group. All symptom scores decreased significantly after treatment in both group. The score decrease of symptoms (except dermatographia ) did not show statistical difference between two groups ( P >0.05). The score decrease of symptoms (except itching on daytime) was significantly greater in the astemizole group than in that of the loratadine group at day 14 after stopping treatment ( P =0.0006～0.0476). At the end of the treatment, efficacy assessment based on symptom score reducing index showed that the affective rate of estemizole and loratadine group were 73.95% and 70.09% ,the clinical cure rate were 49.30% and 49.07%. No serious adverse events were recorded.Conclusion Astemizole and loratadine are safe and effective in the treatment of chronic urticaria, but the effect of astemizole on urticaria symptoms seem significancy lasting than loratadine.
出处
《中国皮肤性病学杂志》
CAS
北大核心
2002年第1期14-16,共3页
The Chinese Journal of Dermatovenereology
关键词
阿司米唑
氯雷他定
荨麻疹
治疗
Astemizole
Loratadine
Chronic idiopathic urticaria
